Actively Recruiting
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Led by Marc Blondon · Updated on 2026-02-17
9200
Participants Needed
1
Research Sites
250 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.
CONDITIONS
Official Title
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Postpartum women after delivery
- Having at least 1 major risk factor or 2 minor risk factors for venous thromboembolism
- Major risk factors include emergency cesarean section, pre-pregnancy BMI 35 kg/m2 or higher, known low-risk thrombophilia, pre-eclampsia, pre-term delivery, peripartum systemic infection, intra-uterine growth restriction, or pregnancy loss
- Minor risk factors include age 35 years or older, pre-pregnancy BMI between 30.0 and 34.9 kg/m2, current smoking, elective cesarean section, postpartum hemorrhage, or antenatal immobility
You will not qualify if you...
- Receiving two or more doses of postpartum low-molecular-weight heparin
- Having any indication for therapeutic anticoagulation
- Having a high risk of postpartum venous thromboembolism
- Having an increased risk of bleeding
- Having a contraindication to heparin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Geneva University Hospitals
Geneva, Switzerland
Actively Recruiting
Research Team
M
Marc Blondon
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here